Recruiting
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants - IM054-003
Actualizada: 5 septiembre, 2023 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Fase
Géneros
Rango de edad
Ubicación (es)
Recruiting
Opciones de tratamiento
Inclusion Criteria: - Body mass index between 18 and 30 kilograms per metered square (kg/m^2), inclusive. - Healthy male and female participants without clinically significant deviation from normal in medical history, physical examination, ECG, and clinical laboratory determinations. - A negative COVID-19 test, which will be performed in the manner mandated by the clinical side where the study is being conducted, at screening and check-in Day -2. Exclusion Criteria: - Participant has any condition that confounds the ability to interpret data from the study. - Participant has any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if the participant was to participate in the study. - Any major surgery or planned surgery (except gastrointestinal [GI] surgery, as described below) within 12 weeks of study intervention administration. Note: Other protocol-defined inclusion/exclusion criteria apply.
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
